Prucalopride (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Prucalopride" in Italian language version.

refsWebsite

Global rank Italian rank

15nih.gov

4^th place

9^th place

10doi.org

2^nd place

7^th place

9oadoi.org

799^th place

22^nd place

3archive.org

6^th place

8^th place

2web.archive.org

1^st place

1europa.eu

68^th place

57^th place

1fda.gov

447^th place

644^th place

1clinicaltrials.gov

5,225^th place

5,296^th place

archive.org

EP. Bouras, M. Camilleri; DD. Burton; S. McKinzie, Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans., in Gut, vol. 44, n. 5, maggio 1999, pp. 682-6, PMID 10205205.
AV. Emmanuel, MA. Kamm; AJ. Roy; K. Antonelli, Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers., in Gut, vol. 42, n. 4, Apr 1998, pp. 511-6, PMID 9616313.
CE. Sloots, A. Rykx; M. Cools; R. Kerstens; M. De Pauw, Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation., in Dig Dis Sci, vol. 55, n. 10, Oct 2010, pp. 2912-21, DOI:10.1007/s10620-010-1229-y, PMID 20428949.

clinicaltrials.gov

Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP) - Full Text View - ClinicalTrials.gov, su clinicaltrials.gov. URL consultato il 20 settembre 2012.

doi.org

dx.doi.org

X. Chen, J. Jiang; T. Liu; H. Liu; W. Zhong; P. Hu, Pharmacokinetics of single and repeated oral doses prucalopride in healthy Chinese volunteers., in Int J Clin Pharmacol Ther, Sep 2012, DOI:10.5414/CP201769, PMID 22943932.
J. Tack, M. Corsetti, Prucalopride : evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation., in Expert Opin Drug Metab Toxicol, vol. 8, n. 10, Oct 2012, pp. 1327-35, DOI:10.1517/17425255.2012.719497, PMID 22985444.
P. Oustamanolakis, J. Tack, Prucalopride for chronic intestinal pseudo-obstruction., in Aliment Pharmacol Ther, vol. 35, n. 3, Feb 2012, pp. 398-9, DOI:10.1111/j.1365-2036.2011.04947.x, PMID 22221087.
AV. Emmanuel, MA. Kamm; AJ. Roy; R. Kerstens; L. Vandeplassche, Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study., in Aliment Pharmacol Ther, vol. 35, n. 1, Jan 2012, pp. 48-55, DOI:10.1111/j.1365-2036.2011.04907.x, PMID 22061077.
CJ. Smart, AN. Ramesh, The successful treatment of acute refractory pseudo-obstruction with prucalopride., in Colorectal Dis, vol. 14, n. 8, Aug 2012, pp. e508, DOI:10.1111/j.1463-1318.2011.02929.x, PMID 22212130.
M. Pennant, R. Orlando; P. Barton; S. Bayliss; K. Routh; C. Meads, Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief., in Health Technol Assess, 15 Suppl 1, maggio 2011, pp. 43-50, DOI:10.3310/hta15suppl1/05, PMID 21609652.
G. Coremans, Prucalopride: the evidence for its use in the treatment of chronic constipation., in Core Evid, vol. 3, n. 1, Jun 2008, pp. 45-54, DOI:10.3355/ce.2008.011, PMID 20694083.
EM. Quigley, L. Vandeplassche; R. Kerstens; J. Ausma, Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study., in Aliment Pharmacol Ther, vol. 29, n. 3, Feb 2009, pp. 315-28, DOI:10.1111/j.1365-2036.2008.03884.x, PMID 19035970.
CE. Sloots, A. Rykx; M. Cools; R. Kerstens; M. De Pauw, Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation., in Dig Dis Sci, vol. 55, n. 10, Oct 2010, pp. 2912-21, DOI:10.1007/s10620-010-1229-y, PMID 20428949.
JD. Gale, The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation., in Adv Ther, vol. 26, n. 5, maggio 2009, pp. 519-30, DOI:10.1007/s12325-009-0027-4, PMID 19444393.

europa.eu

ema.europa.eu

European Medicines Agency -EPAR Archiviato il 31 gennaio 2010 in Internet Archive.

fda.gov

accessdata.fda.gov

Drug Approval Package: Motegrity (prucalopride), su accessdata.fda.gov. URL consultato l'8 ottobre 2021.

nih.gov

ncbi.nlm.nih.gov

MR. Briejer, JP. Bosmans; P. Van Daele; M. Jurzak; L. Heylen; JE. Leysen; NH. Prins; JA. Schuurkes, The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound., in Eur J Pharmacol, vol. 423, n. 1, Jun 2001, pp. 71-83, PMID 11438309.
EP. Bouras, M. Camilleri; DD. Burton; S. McKinzie, Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans., in Gut, vol. 44, n. 5, maggio 1999, pp. 682-6, PMID 10205205.
AC. Poen, RJ. Felt-Bersma; PA. Van Dongen; SG. Meuwissen, Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers., in Aliment Pharmacol Ther, vol. 13, n. 11, Nov 1999, pp. 1493-7, PMID 10571606.
AV. Emmanuel, MA. Kamm; AJ. Roy; K. Antonelli, Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers., in Gut, vol. 42, n. 4, Apr 1998, pp. 511-6, PMID 9616313.
X. Chen, J. Jiang; T. Liu; H. Liu; W. Zhong; P. Hu, Pharmacokinetics of single and repeated oral doses prucalopride in healthy Chinese volunteers., in Int J Clin Pharmacol Ther, Sep 2012, DOI:10.5414/CP201769, PMID 22943932.
J. Tack, M. Corsetti, Prucalopride : evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation., in Expert Opin Drug Metab Toxicol, vol. 8, n. 10, Oct 2012, pp. 1327-35, DOI:10.1517/17425255.2012.719497, PMID 22985444.
P. Oustamanolakis, J. Tack, Prucalopride for chronic intestinal pseudo-obstruction., in Aliment Pharmacol Ther, vol. 35, n. 3, Feb 2012, pp. 398-9, DOI:10.1111/j.1365-2036.2011.04947.x, PMID 22221087.
AV. Emmanuel, MA. Kamm; AJ. Roy; R. Kerstens; L. Vandeplassche, Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study., in Aliment Pharmacol Ther, vol. 35, n. 1, Jan 2012, pp. 48-55, DOI:10.1111/j.1365-2036.2011.04907.x, PMID 22061077.
CJ. Smart, AN. Ramesh, The successful treatment of acute refractory pseudo-obstruction with prucalopride., in Colorectal Dis, vol. 14, n. 8, Aug 2012, pp. e508, DOI:10.1111/j.1463-1318.2011.02929.x, PMID 22212130.
G. Coremans, R. Kerstens; M. De Pauw; M. Stevens, Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial., in Digestion, vol. 67, n. 1-2, 2003, pp. 82-9, PMID 12743445.
M. Pennant, R. Orlando; P. Barton; S. Bayliss; K. Routh; C. Meads, Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief., in Health Technol Assess, 15 Suppl 1, maggio 2011, pp. 43-50, DOI:10.3310/hta15suppl1/05, PMID 21609652.
G. Coremans, Prucalopride: the evidence for its use in the treatment of chronic constipation., in Core Evid, vol. 3, n. 1, Jun 2008, pp. 45-54, DOI:10.3355/ce.2008.011, PMID 20694083.
EM. Quigley, L. Vandeplassche; R. Kerstens; J. Ausma, Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study., in Aliment Pharmacol Ther, vol. 29, n. 3, Feb 2009, pp. 315-28, DOI:10.1111/j.1365-2036.2008.03884.x, PMID 19035970.
CE. Sloots, A. Rykx; M. Cools; R. Kerstens; M. De Pauw, Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation., in Dig Dis Sci, vol. 55, n. 10, Oct 2010, pp. 2912-21, DOI:10.1007/s10620-010-1229-y, PMID 20428949.
JD. Gale, The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation., in Adv Ther, vol. 26, n. 5, maggio 2009, pp. 519-30, DOI:10.1007/s12325-009-0027-4, PMID 19444393.

oadoi.org

X. Chen, J. Jiang; T. Liu; H. Liu; W. Zhong; P. Hu, Pharmacokinetics of single and repeated oral doses prucalopride in healthy Chinese volunteers., in Int J Clin Pharmacol Ther, Sep 2012, DOI:10.5414/CP201769, PMID 22943932.
J. Tack, M. Corsetti, Prucalopride : evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation., in Expert Opin Drug Metab Toxicol, vol. 8, n. 10, Oct 2012, pp. 1327-35, DOI:10.1517/17425255.2012.719497, PMID 22985444.
P. Oustamanolakis, J. Tack, Prucalopride for chronic intestinal pseudo-obstruction., in Aliment Pharmacol Ther, vol. 35, n. 3, Feb 2012, pp. 398-9, DOI:10.1111/j.1365-2036.2011.04947.x, PMID 22221087.
AV. Emmanuel, MA. Kamm; AJ. Roy; R. Kerstens; L. Vandeplassche, Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study., in Aliment Pharmacol Ther, vol. 35, n. 1, Jan 2012, pp. 48-55, DOI:10.1111/j.1365-2036.2011.04907.x, PMID 22061077.
CJ. Smart, AN. Ramesh, The successful treatment of acute refractory pseudo-obstruction with prucalopride., in Colorectal Dis, vol. 14, n. 8, Aug 2012, pp. e508, DOI:10.1111/j.1463-1318.2011.02929.x, PMID 22212130.
M. Pennant, R. Orlando; P. Barton; S. Bayliss; K. Routh; C. Meads, Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief., in Health Technol Assess, 15 Suppl 1, maggio 2011, pp. 43-50, DOI:10.3310/hta15suppl1/05, PMID 21609652.
G. Coremans, Prucalopride: the evidence for its use in the treatment of chronic constipation., in Core Evid, vol. 3, n. 1, Jun 2008, pp. 45-54, DOI:10.3355/ce.2008.011, PMID 20694083.
EM. Quigley, L. Vandeplassche; R. Kerstens; J. Ausma, Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study., in Aliment Pharmacol Ther, vol. 29, n. 3, Feb 2009, pp. 315-28, DOI:10.1111/j.1365-2036.2008.03884.x, PMID 19035970.
JD. Gale, The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation., in Adv Ther, vol. 26, n. 5, maggio 2009, pp. 519-30, DOI:10.1007/s12325-009-0027-4, PMID 19444393.

web.archive.org

European Medicines Agency -EPAR Archiviato il 31 gennaio 2010 in Internet Archive.
Shire Receives European Approval to Use Resolor® (prucalopride) in Men for the Symptomatic Treatment of Chronic Constipation, su web.archive.org, 21 novembre 2017. URL consultato l'8 ottobre 2021 (archiviato dall'url originale il 21 novembre 2017).